{"slideshow_credits": null, "snippet": "The F.D.A.\u2019s committee members said both medicines offered only marginal benefit, reducing the number of hot flashes by only about one a day compared to a placebo.", "abstract": "Outside advisers to Food and Drug Administration soundly reject two drugs vying to become first nonhormonal hot-flash treatments to win agency's approval; say both gabapentin and paroxetine offered only marginal benefit, reducing number of hot flashes by only about one a day compared to placebo.", "section_name": "Business Day", "print_page": "4", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/03/05/business/fda-panel-advises-against-two-medicines-to-treat-hot-flashes.html", "lead_paragraph": "The F.D.A.\u2019s committee members said both medicines offered only marginal benefit, reducing the number of hot flashes by only about one a day compared to a placebo.", "headline": {"main": "F.D.A. Panel Advises Against Two Medicines to Treat Hot Flashes", "print_headline": "F.D.A. Panel Advises Against Two Medicines to Treat Hot Flashes"}, "_id": "513575aacf28d009de003716", "word_count": "817", "multimedia": [], "pub_date": "2013-03-05T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Menopause", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Gabapentin (Drug)", "name": "subject", "is_major": "N", "rank": "2"}, {"value": "Food and Drug Administration", "name": "organizations", "is_major": "N", "rank": "3"}, {"value": "Estrogen", "name": "subject", "is_major": "N", "rank": "4"}, {"value": "Women and Girls", "name": "subject", "is_major": "N", "rank": "5"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "6"}], "blog": [], "subsection_name": null, "type_of_material": "News"}